Immunogenicity, Reactogenicity and Safety Study to Evaluate Two Doses of the Lyophilised Formulation of the Human Rotavirus (HRV) Vaccine When Administered to Healthy Korean Infants Previously Uninfected With HRV.
Phase of Trial: Phase IV
Latest Information Update: 02 Nov 2016
At a glance
- Drugs RIX 4414 (Primary)
- Indications Rotavirus infections
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 18 Nov 2010 Actual end date changed from Jul 2010 to Aug 2010 as reported by ClinicalTrials.gov.
- 04 Aug 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 04 Aug 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.